Teriflunomide , ≥99% , 163451-81-8

CAS NO.：163451-81-8

Empirical Formula: C12H9F3N2O2

Molecular Weight: 270.21

MDL number: MFCD00910058

EINECS: 642-273-4

PRODUCT Properties

• Melting point: 229-232°C
• Boiling point: 410.8±45.0 °C(Predicted)
• Density: 1.424±0.06 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: DMSO: soluble5mg/mL, clear (warmed)
• pka: 5.20±0.50(Predicted)
• form: powder
• color: white to beige
• λmax: 203nm(MeOH)(lit.)
• Merck: 14,9165
• Stability: Hygroscopic
• InChIKey: UTNUDOFZCWSZMS-YFHOEESVSA-N

Description and Uses

In September 2012, the US FDA approved teriflunomide (also referred to as HMR-1726) as a therapy for patients with relapsing forms of multiple sclerosis (MS). Teriflunomide is the second approved oral treatment option for MS, after Gilenya? which was approved in 2010. Teriflunomide, which is the active metabolite of leflunomide (a marketed drug for the treatment of rheumatoid and psoriatic arthritis), is a non?competitive and selective inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in the de novo synthesis of pyrimidines. Although the net effect of inhibition of DHODH by teriflunomide and its therapeutic effect in MS are not clear, it is hypothesized that by inhibiting de novo pyrimidine synthesis, the effector functions of activated lymphocytes are suppressed, thus dampening the effect of an overactive immune system.

A-771726 is the active metabolite of leflunomide, a prodrug approved by the FDA for treatment of rheumatoid arthritis. A-771726 reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines. It prevents activated lymphocytes from accumulating sufficient pyrimidines to support DNA synthesis (IC50s = 0.09, 3.5, and 12.5 μM for rat, mouse, and human, respectively). At higher doses, A-771726 inhibits tyrosine kinases responsible for early T cell and B cell signaling in the G0/G1 phase of the cell cycle. A-771726 has also been shown to inhibit the production of prostaglandin E2 in synoviocytes activated by TNF-α and IL-1α (IC50s = 7 and 3 μM, respectively) as well as inhibit MMP-1 and IL-6 production at concentrations >10 μM.[Cayman Chemical]

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H225-H302+H312+H332-H319
• Precautionary statements: P210-P280-P301+P312-P303+P361+P353-P304+P340+P312-P305+P351+P338
• Hazard Codes: Xn
• Risk Statements: 22
• WGK Germany: 3
• HS Code: 2926.90.4801